MedTrace Logo

COVID-19 Detection Test in Oncology

NCT04367870 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 441

Last updated 2022-06-01

No results posted yet for this study

Summary

EVIDENCE is a non interventional, French, multicenter study. Patients will be screened by local severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoassay in their oncology department (rapid diagnostic test (RDT) or enzyme-linked immunosorbent assay (ELISA)). In patients with positive local SARS-CoV-2 immunoassay, a centralized SARS-CoV-2 ELISA will be performed in order to double check the immune response of all patients considered immune by local immunoassay.

Conditions

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • François-Clément BIDARD · Institut Curie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-23
Primary Completion
2021-05-31
Completion
2022-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04367870 on ClinicalTrials.gov